Trial Profile
Multi-center non-randomized open trial to evaluate the efficacy of azacitidine followed by allo-HSCT for TP53(+) MDS.
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 27 Jun 2022
Price :
$35
*
At a glance
- Drugs Azacitidine (Primary)
- Indications Chronic myelomonocytic leukaemia; Myelodysplastic syndromes
- Focus Therapeutic Use
- Acronyms REPTAT trial
- 20 Jun 2022 Status changed from recruiting to active, no longer recruiting.
- 17 Oct 2017 Status changed from not yet recruiting to recruiting.
- 07 Oct 2017 Planned initiation date changed from 1 Aug 2017 to 5 Oct 2017.